Treatment Outcomes for Frail Patients with Advanced Pancreatic Cancer

A retrospective cohort study from February 2014 to February 2024 includes 63 frail patients with advanced pancreatic ductal adenocarcinoma. The data compares survival outcomes for first-line treatments of gemcitabine, S-1, and stereotactic ablative radiotherapy. The dataset is supplementary material from a study published on figshare.

Use Cases

• Compare overall survival outcomes between gemcitabine and S-1 chemotherapy based on the reported median survival times.
• Analyze the association between stereotactic ablative radiotherapy and systemic chemotherapy in borderline resectable or locally advanced disease based on hazard ratios.
• Investigate treatment efficacy in subgroups such as patients with tumor size ≥4 cm or peritoneal metastasis based on the described findings.
• Evaluate adverse event profiles between chemotherapy and radiotherapy based on the reported frequency of hematologic and non-hematologic events.

Strengths

• Includes 63 patient records with defined frailty criteria (age ≥80 or ECOG performance status ≥2).
• Provides specific median survival times (7.70 months and 4.33 months) for metastatic disease.
• Uses propensity score-based overlap weighting for comparative analysis.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• Data is from a single-center study, which may limit generalizability.

Provenance

Source

figshare admin karger

Collection Method

Single-center retrospective cohort study.

Time Range

February 2014 to February 2024

Freshness

Last updated 2026-05-05 05:55:15; freshness should be verified.